{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:11:30Z","timestamp":1791558690103,"version":"4.3.4"},"reference-count":284,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014584","name":"Ignyta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"Medimmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"Medimmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BMS"},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006413","name":"ARIAD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gen\u00f3mica"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jtho.2020.03.006","type":"journal-article","created":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T02:42:29Z","timestamp":1584153749000},"page":"914-947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"title":["Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations"],"prefix":"10.1016","volume":"15","author":[{"given":"Jordi","family":"Remon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Garon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Gettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy S.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leora","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mezquita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt A.","family":"Schalper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinandos","family":"Skoulidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio V.","family":"Scagliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2020.03.006_bib1","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib3","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2020.03.006_bib4","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib5","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib6","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib7","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib8","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2012small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib9","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib10","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S1470-2045(19)30407-3","article-title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","volume":"20","author":"Antonia","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib11","doi-asserted-by":"crossref","first-page":"dju435","DOI":"10.1093\/jnci\/dju435","article-title":"Objective measurement and clinical significance of TILs in non-small cell lung cancer","volume":"107","author":"Schalper","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2020.03.006_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"Velcheti","year":"2014","journal-title":"Lab Invest"},{"key":"10.1016\/j.jtho.2020.03.006_bib13","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1158\/1078-0432.CCR-18-1316","article-title":"Molecular profiling of cohorts of tumor samples to guide clinical development of pembrolizumab as monotherapy","volume":"25","author":"Ayers","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib14","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib15","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","article-title":"PD-L1 expression in lung cancer","volume":"11","author":"Yu","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206370","article-title":"Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States","volume":"13","author":"Velcheti","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2020.03.006_bib17","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.2017.74.7642","article-title":"Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer","volume":"35","author":"B\u00fcttner","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib18","doi-asserted-by":"crossref","first-page":"71608","DOI":"10.18632\/oncotarget.12264","article-title":"Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer","volume":"7","author":"Del Mar Valenzuela-Membrives","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2020.03.006_bib19","doi-asserted-by":"crossref","first-page":"14381","DOI":"10.1038\/ncomms14381","article-title":"Neutrophils dominate the immune cell composition in non-small cell lung cancer","volume":"8","author":"Kargl","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2020.03.006_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89014","article-title":"Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes","volume":"1","author":"Lizotte","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtho.2020.03.006_bib21","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.3389\/fimmu.2018.03101","article-title":"Immune cell composition in human non-small cell lung cancer","volume":"9","author":"Stankovic","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2020.03.006_bib22","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2020.03.006_bib23","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1159\/000438523","article-title":"Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis","volume":"37","author":"Geng","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.jtho.2020.03.006_bib24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jtho.2016.01.015","article-title":"The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer","volume":"11","author":"Bremnes","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib25","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","article-title":"Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis","volume":"25","author":"Datar","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","article-title":"Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2020.03.006_bib27","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1051922","article-title":"A\u00a0high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality","volume":"4","author":"Zhu","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2020.03.006_bib28","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3389\/fimmu.2017.01830","article-title":"Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?","volume":"8","author":"Colbeck","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2020.03.006_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050946","article-title":"Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2020.03.006_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1164\/rccm.201508-1545CI","article-title":"Macrophages, inflammation, and lung cancer","volume":"193","author":"Conway","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets\u00a0in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib32","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.1158\/1078-0432.CCR-15-2443","article-title":"Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients","volume":"22","author":"Parra","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1158\/1078-0432.CCR-17-2156","article-title":"Low PD-1 expression in cytotoxic CD8+ tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value","volume":"24","author":"Mazzaschi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib34","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/j.jtho.2018.09.012","article-title":"Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations","volume":"13","author":"Toki","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib35","first-page":"129","article-title":"Classifying non-small cell lung cancer by status of programmed cell death ligand 1 and tumor-infiltrating lymphocytes on tumor cells","volume":"9","author":"Cui","year":"2018","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib36","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2020.03.006_bib37","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1158\/1078-0432.CCR-15-2834","article-title":"Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration","volume":"22","author":"Ock","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejca.2014.12.006","article-title":"PD-L1 expression in small cell neuroendocrine carcinomas","volume":"51","author":"Schultheis","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib39","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/JTO.0000000000000414","article-title":"Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer","volume":"10","author":"Ishii","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.lungcan.2017.03.006","article-title":"PD-L1 expression in neuroendocrine tumors of the lung","volume":"108","author":"Tsuruoka","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib41","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejca.2018.06.023","article-title":"The role of immune microenvironment in small-cell lung cancer: distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes","volume":"101","author":"Bonanno","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","article-title":"Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC)","volume":"7","author":"Carvajal-Hausdorf","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13000-018-0712-1","article-title":"Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors","volume":"13","author":"Wang","year":"2018","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.jtho.2020.03.006_bib44","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib45","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1200\/JCO.2017.72.5069","article-title":"Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib46","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jtho.2019.03.028","article-title":"Immune cell infiltration may be a key determinant of long-term survival in small cell lung cancer","volume":"14","author":"Muppa","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib47","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00262-018-2131-2","article-title":"Defective HLA class I antigen processing machinery in cancer","volume":"67","author":"Cai","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtho.2020.03.006_bib48","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","article-title":"Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays","volume":"87","author":"Chapel","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2020.03.006_bib50","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the Bio-MAPS cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2020.03.006_bib52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ajco.12788","article-title":"PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma","volume":"14","author":"Nguyen","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib53","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jtho.2017.09.1968","article-title":"Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma","volume":"13","author":"Patil","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib54","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic T cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib55","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1002\/cncr.26143","article-title":"Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma","volume":"117","author":"Burt","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses","volume":"18","author":"Spranger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib58","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-med-060116-022926","article-title":"Molecular and genomic determinants of response to immune checkpoint inhibition in cancer","volume":"69","author":"Jenkins","year":"2018","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib59","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","article-title":"Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape","volume":"48","author":"Wellenstein","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2020.03.006_bib60","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2020.03.006_bib61","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib62","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jtho.2020.03.006_bib63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mdw436","article-title":"Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up","volume":"28","author":"Kadara","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib64","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2019.37.15_suppl.102","article-title":"Association of STK11\/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer","volume":"37","author":"Skoulidis","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib65","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2020.03.006_bib66","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.jtho.2020.03.006_bib67","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2020.03.006_bib68","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","article-title":"STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib69","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1131379","article-title":"PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations","volume":"5","author":"Scheel","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2020.03.006_bib70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","article-title":"Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer","volume":"9","author":"Kitajima","year":"2019","journal-title":"Cancer Discov"},{"issue":"suppl","key":"10.1016\/j.jtho.2020.03.006_bib71","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1016\/j.jtho.2019.08.442","article-title":"OA07.02 LKB1 mutations in metastatic non-small cell lung cancer (mNSCLC): prognostic value in the real world","volume":"14","author":"Golozar","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2020.03.006_bib72","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/j.jtho.2019.08.428","article-title":"OA04.07 mutations associated with sensitivity or resistance to immunotherapy in mNSCLC: analysis from the MYSTIC trial","volume":"14","author":"Rizvi","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib73","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2020.03.006_bib74","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2020.03.006_bib75","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmet.2018.02.006","article-title":"Synergy between the KEAP1\/NRF2 and PI3K pathways drives non-small-cell lung cancer with an altered immune microenvironment","volume":"27","author":"Best","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.jtho.2020.03.006_bib76","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1038\/s41467-019-12164-y","article-title":"Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma","volume":"10","author":"Best","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2020.03.006_bib77","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1038\/s41467-018-05861-7","article-title":"Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogramming","volume":"9","author":"Olagnier","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2020.03.006_bib78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/annonc\/mdw437","article-title":"Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function","volume":"28","author":"Choi","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib79","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/s41467-019-09762-1","article-title":"Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2020.03.006_bib80","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2020.03.006_bib81","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database","volume":"28","author":"Petitjean","year":"2007","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jtho.2020.03.006_bib82","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib83","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2016.05.001","article-title":"Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status","volume":"97","author":"Cha","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib84","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature08462","article-title":"Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma","volume":"462","author":"Meylan","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2020.03.006_bib85","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/0008-5472.CAN-14-3051","article-title":"Correlation between density of CD8+ T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy","volume":"75","author":"Maby","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib86","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1172\/JCI84940","article-title":"Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer","volume":"126","author":"Mehnert","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtho.2020.03.006_bib87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215381","article-title":"Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1\/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer","volume":"14","author":"Wen","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2020.03.006_bib88","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib89","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2020.03.006_bib90","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1108514","article-title":"EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1\u03b1 and STAT3","volume":"5","author":"Koh","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2020.03.006_bib91","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/1078-0432.CCR-18-1102","article-title":"Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers","volume":"25","author":"Offin","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib92","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1200\/JCO.2016.34.15_suppl.9017","article-title":"Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1\/PD-L1 targeted therapies","volume":"34","author":"Spigel","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib93","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib94","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.4049\/jimmunol.1600576","article-title":"Lung cancer subtypes generate unique immune responses","volume":"197","author":"Busch","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jtho.2020.03.006_bib95","article-title":"Immunophenotype and response to immunotherapy of RET-rearranged lung cancers","volume":"3","author":"Offin","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib96","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET Registry","volume":"30","author":"Mazi\u00e8res","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib97","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1200\/JCO.2018.36.15_suppl.9060","article-title":"PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers","volume":"36","author":"Lai","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib98","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/annonc\/mdy334","article-title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","volume":"29","author":"Sabari","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib99","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jtho.2018.04.024","article-title":"BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors","volume":"13","author":"Dudnik","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib100","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jtho.2019.02.008","article-title":"PD-L1 expression, tumor mutational burden, and cancer gene mutations are stronger Predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer","volume":"14","author":"Negrao","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib101","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40425-016-0177-2","article-title":"Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy","volume":"4","author":"Agrawal","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib102","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/annonc\/mdx235","article-title":"Assessment of nivolumab benefit-risk profile of a 240-mg flat dose\u00a0relative to a 3-mg\/kg dosing regimen in patients\u00a0with advanced tumors","volume":"28","author":"Zhao","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib103","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/annonc\/mdy408","article-title":"Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer","volume":"29","author":"Long","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib104","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib106","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib107","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.2018.36.15_suppl.3062","article-title":"A\u00a0six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation","volume":"36","author":"Lala","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib108","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2020.03.006_bib110","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib111","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cpt.982","article-title":"Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status","volume":"103","author":"Baverel","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtho.2020.03.006_bib113","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bcp.12323","article-title":"Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma","volume":"78","author":"Feng","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtho.2020.03.006_bib114","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib115","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib116","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2019.02.016","article-title":"Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: what is the economic impact?","volume":"113","author":"Bayle","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib117","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project","volume":"13","author":"Tsao","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib118","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2020.03.006_bib119","first-page":"v851","article-title":"IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (TX) in PD-L1\u2013selected NSCLC","volume":"30","author":"Spigel","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib120","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib121","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","article-title":"Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression","volume":"30","author":"Aguilar","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl 10","key":"10.1016\/j.jtho.2020.03.006_bib122","first-page":"x39","article-title":"Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC","volume":"29","author":"Rizvi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib123","doi-asserted-by":"crossref","first-page":"CT074","DOI":"10.1158\/1538-7445.AM2019-CT074","article-title":"Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): blood and tissue TMB analysis from MYSTIC, a phase III study of first-line durvalumab \u00b1 tremelimumab vs chemotherapy","volume":"79","author":"Peters","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib124","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2020.03.006_bib125","first-page":"v851","article-title":"Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)","volume":"30","author":"Socinski","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib127","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jamaoncol.2019.3221","article-title":"Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden","volume":"5","author":"Bomze","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib128","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jtho.2018.08.004","article-title":"24-month overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer","volume":"14","author":"Borghaei","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib129","first-page":"JCO1903136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"9","author":"Gadgeel","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2020.03.006_bib130","first-page":"v851","article-title":"Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: tissue TMB (TTMB) and outcomes in KEYNOTE-021, 189, and 407","volume":"30","author":"Paz-Ares","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl 8","key":"10.1016\/j.jtho.2020.03.006_bib131","doi-asserted-by":"crossref","first-page":"viii743","DOI":"10.1093\/annonc\/mdy424.066","article-title":"IMpower132: efficacy of atezolizumab (atezo)\u00a0+ carboplatin (carbo)\/cisplatin (cis)\u00a0+ pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)","volume":"29","author":"Barlesi","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib132","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1200\/JCO.2018.36.15_suppl.9002","article-title":"Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo)\u00a0+ chemotherapy (chemo) \u00b1 bevacizumab (bev) vs chemo\u00a0+ bev in 1L nonsquamous (NSQ) NSCLC","volume":"36","author":"Socinski","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 18","key":"10.1016\/j.jtho.2020.03.006_bib133","doi-asserted-by":"crossref","first-page":"LBA9000","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA9000","article-title":"IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab\u00a0+ carboplatin\u00a0+ paclitaxel or nab-paclitaxel vs carboplatin\u00a0+ nab-paclitaxel as 1L therapy in advanced squamous NSCLC","volume":"36","author":"Jotte","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2020.03.006_bib134","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.1016\/j.jtho.2019.08.484","article-title":"OA14.02 IMpower131: final OS results of carboplatin\u00a0+ nab-paclitaxel \u00b1 atezolizumab in advanced squamous NSCLC","volume":"14","author":"Jotte","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"Suppl 11","key":"10.1016\/j.jtho.2020.03.006_bib135","doi-asserted-by":"crossref","first-page":"xi67","DOI":"10.1093\/annonc\/mdz453.004","article-title":"LBA3 nivolumab (NIVO)\u00a0+ platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis","volume":"30","author":"Paz-Ares","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib136","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study","volume":"36","author":"Gettinger","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2020.03.006_bib137","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1016\/j.jtho.2019.08.486","article-title":"OA14.04 five-year outcomes from the randomized, phase 3 trials\u00a0CheckMate 017\/057: nivolumab vs docetaxel in\u00a0previously treated NSCLC","volume":"14","author":"Gettinger","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib138","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/ijms20040959","article-title":"Realizing the clinical potential of immunogenic cell death in cancer chemotherapy and radiotherapy","volume":"20","author":"Rapoport","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2020.03.006_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","article-title":"Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect?","volume":"102","author":"Gerber","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jtho.2020.03.006_bib140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jtho.2020.03.006_bib141","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs\u00a0in\u00a0cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib142","first-page":"187","article-title":"Combinatorial strategies for the induction of immunogenic cell death","volume":"6","author":"Bezu","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2020.03.006_bib143","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.gendis.2018.05.003","article-title":"Immunogenic effects of chemotherapy-induced tumor cell death","volume":"5","author":"Wang","year":"2018","journal-title":"Genes Dis"},{"key":"10.1016\/j.jtho.2020.03.006_bib144","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fcell.2019.00050","article-title":"Immunogenic cell death and immunotherapy of multiple myeloma","volume":"7","author":"Serrano-Del Valle","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jtho.2020.03.006_bib145","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.01.003","article-title":"Combining chemotherapy with PD-1 blockade in NSCLC","volume":"186","author":"Mathew","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jtho.2020.03.006_bib146","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2020.03.006_bib147","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib148","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib149","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/annonc\/mdy553","article-title":"Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)","volume":"30","author":"Peters","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2019.05.001","article-title":"Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-the ETOP NICOLAS trial","volume":"133","author":"Peters","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib151","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.3390\/ijms20092173","article-title":"Stereotactic ablative radiotherapy combined with immune checkpoint inhibitors reboots the immune response assisted by immunotherapy in metastatic lung cancer: a systematic review","volume":"20","author":"Chicas-Sett","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2020.03.006_bib152","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib153","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2020.03.006_bib154","first-page":"v460","article-title":"Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)","volume":"28","author":"Spigel","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2020.03.006_bib155","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.1016\/j.jtho.2019.08.483","article-title":"OA14.01 KEYNOTE-024 3-year survival update: pembrolizumab vs platinum-based chemotherapy for advanced non\u2013small-cell lung cancer","volume":"14","author":"Reck","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 8","key":"10.1016\/j.jtho.2020.03.006_bib156","doi-asserted-by":"crossref","first-page":"viii749","DOI":"10.1093\/annonc\/mdy424.075","article-title":"Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)","volume":"29","author":"Herbst","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl 13","key":"10.1016\/j.jtho.2020.03.006_bib157","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1158\/1538-7445.AM2018-1719","article-title":"Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer","volume":"78","author":"Cascone","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib158","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib159","doi-asserted-by":"crossref","first-page":"8534","DOI":"10.1200\/JCO.2019.37.15_suppl.8534","article-title":"Neoadjuvant pembrolizumab (pembro) for early stage non-small cell lung cancer (NSCLC): updated report of a phase I study, MK3475-223","volume":"37","author":"Bar","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib160","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2019.37.15_suppl.8503","article-title":"Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): interim analysis and biomarker data from a multicenter study (LCMC3)","volume":"37","author":"Kwiatkowski","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib161","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2019.37.15_suppl.8504","article-title":"Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): clinical and correlative results from the NEOSTAR study","volume":"37","author":"Cascone","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib162","doi-asserted-by":"crossref","unstructured":"Gao S, Li N, Gao S, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC [e-pub ahead of print]. J\u00a0Thorac Oncol. https:\/\/doi.org\/10.1016\/j.jtho.2020.01.017. Accessed April 6, 2020.","DOI":"10.1016\/j.jtho.2020.01.017"},{"key":"10.1016\/j.jtho.2020.03.006_bib163","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib164","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/j.jtho.2019.08.480","article-title":"OA13.05 NADIM study: updated clinical researc-h and outcomes","volume":"14(suppl)","author":"Provencio","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib165","doi-asserted-by":"crossref","first-page":"8532","DOI":"10.1200\/JCO.2018.36.15_suppl.8532","article-title":"Neoadjuvant atezolizumab\u00a0+ chemotherapy in resectable non-small cell lung cancer (NSCLC)","volume":"36","author":"Shu","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib166","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib167","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib168","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40425-018-0398-7","article-title":"Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity","volume":"6","author":"Bakos","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib169","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib170","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41571-018-0111-2","article-title":"Hyperprogressive disease: recognizing a novel pattern to improve patient management","volume":"15","author":"Champiat","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib171","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib172","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib173","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib174","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/cncr.31999","article-title":"Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities","volume":"125","author":"Kanjanapan","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib175","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy","volume":"4","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib176","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/annonc\/mdz123","article-title":"Hyperprogressive disease during PD-1\/PD-L1 blockade in patients with non-small-cell lung cancer","volume":"30","author":"Kim","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib177","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10120-018-00922-8","article-title":"Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer","volume":"22","author":"Sasaki","year":"2019","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib178","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000488","article-title":"Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer","volume":"4","author":"Aoki","year":"2019","journal-title":"ESMO Open"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib179","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2018.36.15_suppl.3032","article-title":"Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials","volume":"36","author":"Matos","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib180","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib181","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","article-title":"Antibody-Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade","volume":"25","author":"Lo Russo","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"suppl 10","key":"10.1016\/j.jtho.2020.03.006_bib182","doi-asserted-by":"crossref","first-page":"x39","DOI":"10.1093\/annonc\/mdy511","article-title":"Fast progression in patients treated with a checkpoint inhibitor (CPI) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC","volume":"29","author":"Gandara","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib183","doi-asserted-by":"crossref","first-page":"9107","DOI":"10.1200\/JCO.2019.37.15_suppl.9107","article-title":"Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO)","volume":"37","author":"Ferrara","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib184","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jtho.2019.05.033","article-title":"Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced non-small cell lung cancer treated with immune checkpoint inhibitor","volume":"14","author":"Kim","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib185","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib186","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jtho.2019.06.010","article-title":"Clinical activity, tolerability, and long-term follow-up of durvalumab in patients with advanced NSCLC","volume":"14","author":"Antonia","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib187","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jtho.2020.03.006_bib188","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jtho.2020.03.006_bib189","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancera-a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib190","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib191","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib192","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jtho.2020.03.006_bib193","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib194","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2020.03.006_bib195","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2020.03.006_bib196","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib197","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","article-title":"CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2020.03.006_bib198","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.athoracsur.2017.03.038","article-title":"Initial experience with lung cancer resection after treatment with T-cell checkpoint inhibitors","volume":"104","author":"Chaft","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2020.03.006_bib199","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jtho.2018.03.008","article-title":"Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non-small cell lung cancer","volume":"13","author":"Gettinger","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib200","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-18-1127","article-title":"Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer","volume":"79","author":"Anagnostou","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib201","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early assessment of lung cancer immunotherapy response via circulating tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib202","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jtho.2020.03.006_bib203","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib204","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib205","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib206","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"4","author":"Fuc\u00e0","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2020.03.006_bib207","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib208","doi-asserted-by":"crossref","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","article-title":"Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood","volume":"113","author":"Klocke","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jtho.2020.03.006_bib209","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2019.01.014","article-title":"Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies","volume":"130","author":"Yoneshima","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib210","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2016.2238","article-title":"Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options","volume":"2","author":"Khan","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib211","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/j.jtho.2019.03.019","article-title":"Autoimmune diseases and lung cancer: a Mendelian randomization study","volume":"14","author":"Zhou","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib212","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lungcan.2017.11.024","article-title":"How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national\u00a0SEER-Medicare analysis","volume":"115","author":"Khan","year":"2018","journal-title":"Lung Cancer"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib213","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2019.37.15_suppl.110","article-title":"Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs)","volume":"37","author":"Khozin","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib214","doi-asserted-by":"crossref","first-page":"6583","DOI":"10.1200\/JCO.2019.37.15_suppl.6583","article-title":"Real-world prevalence of autoimmune disease (AD) among patients (pts) receiving immune checkpoint inhibitors (ICI) in ASCO\u2019s CancerLinQ database","volume":"37","author":"Chen","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib215","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib216","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib217","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2020.03.006_bib218","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jtho.2019.07.004","article-title":"Is there room for immune checkpoint inhibitors in patients who have NSCLC with autoimmune diseases?","volume":"14","author":"Remon","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib219","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jtho.2020.03.006_bib220","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jtho.2020.03.006_bib221","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib222","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.2019.37.15_suppl.4004","article-title":"Results of KEYNOTE-240: phase 3 study of pembrolizumab (pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC)","volume":"37","author":"Finn","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib223","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur J Cancer"},{"issue":"suppl 1","key":"10.1016\/j.jtho.2020.03.006_bib224","first-page":"S658","article-title":"Immune checkpoint inhibitors in solid tumor patients with chronic hepatitis C virus infection: a prospective case-series","volume":"5","author":"Hosry","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jtho.2020.03.006_bib225","doi-asserted-by":"crossref","unstructured":"Byeon S, Cho JH, Jung HA, et\u00a0al. PD-1 inhibitors for non-small cell lung cancer patients with special issues: real-world evidence [e-pub ahead of print]. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.2868. Accessed April 6, 2020.","DOI":"10.1002\/cam4.2868"},{"key":"10.1016\/j.jtho.2020.03.006_bib226","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib227","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/COH.0000000000000326","article-title":"Lung cancer in persons with HIV","volume":"12","author":"Sigel","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jtho.2020.03.006_bib228","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/1471-2407-11-272","article-title":"Lung cancer in HIV patients and their parents: a Danish cohort study","volume":"11","author":"Engsig","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib229","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1001\/jamainternmed.2017.4349","article-title":"Lung cancer mortality associated with smoking and smoking cessation among people living with HIV in the United States","volume":"177","author":"Reddy","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib230","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib231","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib232","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/JCO.2019.37.15_suppl.2501","article-title":"Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected","volume":"37","author":"Gonz\u00e1lez-Cao","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2020.03.006_bib233","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/j.jtho.2019.08.424","article-title":"OA04.02 CheckMate 817: first-line nivolumab\u00a0+ ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib234","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib235","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1200\/JCO.2007.12.5435","article-title":"Lung cancer in elderly patients: an analysis of the Surveillance, Epidemiology, and End Results database","volume":"25","author":"Owonikoko","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib236","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2020.03.006_bib237","first-page":"v460","article-title":"Nivolumab in previously treated patients with metastatic squamous NSCLC: results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged \u226570 years and with poor performance status","volume":"28","author":"Popat","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib238","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.lungcan.2019.07.004","article-title":"Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1\u2013positive advanced non\u2013small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies","volume":"135","author":"Nosaki","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib239","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jtho.2019.05.010","article-title":"Safety, efficacy, and patient-reported health-related quality of life and\u00a0symptom burden with nivolumab in patients with advanced non\u2013small cell lung cancer, including patients\u00a0aged 70 years or older with poor performance status (CheckMate 153)","volume":"14","author":"Spigel","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2020.03.006_bib240","doi-asserted-by":"crossref","first-page":"ii61","DOI":"10.1093\/annonc\/mdz063.067","article-title":"Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly\u00a0patients (EP)","volume":"30","author":"Corral de la Fuente","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2020.03.006_bib241","doi-asserted-by":"crossref","first-page":"S1289","DOI":"10.1016\/j.jtho.2016.11.1823","article-title":"P3.02C-028 outcomes of nivolumab in elderly patients (pts) with non-small cell lung cancer (NSCLC)","volume":"12","author":"Bagley","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib242","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.1240527","article-title":"Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment","volume":"342","author":"Iida","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jtho.2020.03.006_bib243","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jtho.2020.03.006_bib244","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jtho.2020.03.006_bib245","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jtho.2020.03.006_bib246","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","article-title":"The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC","volume":"14","author":"Jin","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib247","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib248","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","article-title":"A\u00a0defined commensal consortium elicits CD8 T cells and anti-cancer immunity","volume":"565","author":"Tanoue","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2020.03.006_bib249","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.jtho.2019.08.061","article-title":"PL02.11 overall survival with durvalumab plus etoposide-platinum in first-line extensive-stage SCLC: results from the CASPIAN study","volume":"14","author":"Paz-Ares","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2020.03.006_bib250","doi-asserted-by":"crossref","first-page":"ii77","DOI":"10.1093\/annonc\/mdz094","volume":"30","author":"Owonikoko","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib251","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jtho.2018.05.002","article-title":"Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC)","volume":"13","author":"Gadgeel","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 10","key":"10.1016\/j.jtho.2020.03.006_bib252","first-page":"x39","article-title":"Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): results from CheckMate 331","volume":"29","author":"Reck","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib253","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jtho.2019.01.008","article-title":"A\u00a0randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 trial","volume":"14","author":"Pujol","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib254","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2018.36.15_suppl.8506","article-title":"Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158","volume":"36","author":"Chung","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib255","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","article-title":"Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032","volume":"14","author":"Ready","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib256","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"issue":"suppl 8","key":"10.1016\/j.jtho.2020.03.006_bib257","doi-asserted-by":"crossref","first-page":"viii596","DOI":"10.1093\/annonc\/mdy298.001","article-title":"Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory\/resistant ED-SCLC from arm A of the phase II BALTIC study","volume":"29","author":"Bondarenko","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2020.03.006_bib258","doi-asserted-by":"crossref","first-page":"S393","DOI":"10.1016\/j.jtho.2016.11.446","article-title":"MA09.05 nivolumab alone or with ipilimumab in recurrent small cell lung cancer (SCLC): 2-year survival and updated analyses from the Checkmate 032 trial","volume":"12","author":"Hellmann","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib259","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","article-title":"Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort","volume":"15","author":"Ready","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib260","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2020.03.006_bib261","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1016\/j.jtho.2018.08.277","article-title":"OA08.03 phase II trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis","volume":"13","author":"Desai","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib262","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib263","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib264","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1200\/JCO.2018.36.15_suppl.8563","article-title":"Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow-up from JAVELIN solid tumor","volume":"36","author":"Hassan","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib265","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed\u00a0malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2020.03.006_bib266","doi-asserted-by":"crossref","first-page":"v747","DOI":"10.1093\/annonc\/mdz266","article-title":"2nd\/3rd-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)","volume":"30","author":"Zalcman","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib267","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2020.03.006_bib268","first-page":"v851","article-title":"A\u00a0multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM) \u2013 results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"30","author":"Popat","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib269","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"suppl","key":"10.1016\/j.jtho.2020.03.006_bib270","doi-asserted-by":"crossref","first-page":"S338","DOI":"10.1016\/j.jtho.2018.08.276","article-title":"OA08.02 DREAM - a phase 2 trial of durvalumab with first line chemotherapy in mesothelioma: final result","volume":"13","author":"Nowak","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2020.03.006_bib271","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib272","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2020.03.006_bib273","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib274","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182665","article-title":"Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors","volume":"12","author":"Arbour","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2020.03.006_bib275","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.18632\/oncotarget.24075","article-title":"A\u00a0comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma","volume":"9","author":"Sakane","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2020.03.006_bib276","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib277","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib278","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib279","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2020.03.006_bib280","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib281","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtho.2020.03.006_bib282","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-18-2882","article-title":"Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis","volume":"25","author":"Labadie","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2020.03.006_bib283","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.03.006_bib284","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jtho.2020.03.006_bib285","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41419-017-0238-6","article-title":"Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in\u00a0vitro and in mice","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jtho.2020.03.006_bib286","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11684-019-0683-y","article-title":"Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy","volume":"13","author":"Zhang","year":"2019","journal-title":"Front Med"},{"key":"10.1016\/j.jtho.2020.03.006_bib287","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jtho.2017.10.001","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for\u00a0thoracic malignancies","volume":"13","author":"Kiesgen","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2020.03.006_bib288","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.2019.37.15_suppl.2511","article-title":"Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: safety and preliminary efficacy in combination with anti-PD-1 agent","volume":"37","author":"Adusumilli","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"updated-by":[{"DOI":"10.1016\/j.jtho.2020.07.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000}}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086420301982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086420301982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T17:02:14Z","timestamp":1695920534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086420301982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":284,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1556086420301982"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2020.03.006","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2020.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}